Stereotactic Irradiation of GH-Secreting Pituitary Adenomas

International Journal of Endocrinology - Tập 2012 - Trang 1-7 - 2012
Giuseppe Minniti1,2, Claudia Scaringi2, Dante Amelio3, R. Maurizi Enrici2
1Department of Neuroscience, Neuromed Institute, 86077 Pozzilli, Italy
2Department of Radiation Oncology, Sant’Andrea Hospital, University Sapienza, 00189 Rome, Italy
3ATreP, Agenzia Provinciale per la Protonterapia, 38122 Trento, Italy

Tóm tắt

Radiotherapy (RT) is often employed in patients with acromegaly refractory to medical and/or surgical interventions in order to prevent tumour regrowth and normalize elevated GH and IGF-I levels. It achieves tumour control and hormone normalization up to 90% and 70% of patients at 10–15 years. Despite the excellent tumour control, conventional RT is associated with a potential risk of developing late toxicity, especially hypopituitarism, and its role in the management of patients with GH-secreting pituitary adenomas remains a matter of debate. Stereotactic techniques have been developed with the aim to deliver more localized irradiation and minimize the long-term consequences of treatment, while improving its efficacy. Stereotactic irradiation can be given in a single dose as stereotactic radiosurgery (SRS) or in multiple doses as fractionated stereotactic radiotherapy (FSRT). We have reviewed the recent published literature on stereotactic techniques for GH-secreting pituitary tumors with the aim to define the efficacy and potential adverse effects of each of these techniques.

Từ khóa


Tài liệu tham khảo

10.1210/er.2002-0022

2006, The New England Journal of Medicine, 355, 2558, 10.1056/NEJMra062453

10.1677/erc.0.0100611

10.1046/j.1365-2265.2001.01343.x

10.1530/eje.0.1480193

2011, Nature Reviews Endocrinology, 7, 291, 10.1038/nrendo.2011.42

2000, Journal of Clinical Endocrinology and Metabolism, 85, 3779, 10.1210/jcem.85.10.6870

10.1210/jc.85.7.2476

10.1111/j.1365-2265.2005.02199.x

10.1210/jc.2005-1616

10.1007/s11154-008-9106-0

10.1111/j.1365-2265.2004.02138.x

10.1227/01.NEU.0000223512.09115.3E

10.1227/01.NEU.0000341630.42160.18

10.1586/ern.09.150

10.1016/S0360-3016(98)00276-4

10.1016/j.radonc.2004.06.008

10.1016/S0360-3016(03)00088-9

10.1016/S0360-3016(00)01562-5

10.1186/1748-717X-5-1

1988, Journal of Neurosurgery, 88, 43

10.1016/S0360-3016(02)04380-8

10.1007/s007010050121

1998, Stereotactic and Functional Neurosurgery, 70, 95, 10.1159/000056412

1998, Journal of Neurosurgery, 88, 1002, 10.3171/jns.1998.88.6.1002

1999, Stereotactic and Functional Neurosurgery, 72, 101, 10.1159/000056445

1999, Stereotactic and Functional Neurosurgery, 72, 125, 10.1159/000056448

1999, Stereotactic and Functional Neurosurgery, 72, 88, 10.1159/000056444

2000, Journal of Neurosurgery, 93, 19, 10.3171/jns.2000.93.1.0019

10.1159/000048393

10.1210/jc.85.3.1287

2001, Journal of Neurosurgery, 95, 285, 10.3171/jns.2001.95.2.0285

2002, Journal of Neurosurgery, 97, 525, 10.3171/jns.2002.97.3.0525

10.1210/jc.2002-020356

2003, Yonsei Medical Journal, 44, 602, 10.3349/ymj.2003.44.4.602

10.1210/jc.2002-021663

2003, Neurosurgical Focus, 14

10.1210/jc.2005-0311

10.1055/s-2005-837552

10.3171/jns.2005.102.s_supplement.0119

2006, Clinical Endocrinology, 64, 588, 10.1111/j.1365-2265.2006.02513.x

10.1002/cncr.22128

2007, Endocrine Practice, 13, 726, 10.4158/EP.13.7.726

10.3171/jns.2007.106.5.833

10.1530/EJE-07-0189

10.1227/01.neu.0000333297.41813.3d

10.1210/jc.2008-0135

10.1111/j.1365-2265.2009.03589.x

10.1186/1756-9966-28-36

10.1007/s11060-010-0172-2

10.1016/j.jocn.2009.05.040

2010, The Journal of Clinical Endocrinology & Metabolism, 95, 3141, 10.1210/jc.2009-2670

2003, Neurosurgery, 52, 1436, 10.1227/01.NEU.0000064809.59806.E8

10.1210/jc.2004-1152

10.1016/j.ijrobp.2003.12.012

10.1016/j.ijrobp.2004.09.058

10.1111/j.1365-2265.2006.02506.x

2009, Canadian Journal of Neurological Sciences, 36, 468, 10.1017/S0317167100007800

10.1530/EJE-09-1045

10.1055/s-2004-830261

10.1007/s11102-007-0004-3

10.1016/S0360-3016(98)00256-9